Back to Search
Start Over
Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.
- Source :
-
Neoplasma [Neoplasma] 2012; Vol. 59 (4), pp. 440-9. - Publication Year :
- 2012
-
Abstract
- Unlabelled: In a phase II clinical study, pretreated multiple myeloma patients with relapsing or stable disease received autologous anticancer vaccine containing dendritic cells loaded with Id-protein. Patients received a total of 6 vaccine doses intradermally in monthly intervals. No clinical responses were observed. During the follow-up with a median of 33.1 months (range: 11-43 months), the disease remained stable in 7/11 (64%) of patients. Immune responses measured by ELISpot were noted in 3/11 (27%) and DTH skin test for Id-protein was positive in 8/11 (73%) of patients; out of those, 1/11 (9%) and 5/11 (46%), respectively, had preexisting immune response to Id-protein before the vaccination began. Outcomes were compared to those of a control group of 13 patients. A trend to lower cumulative incidence of progression in the vaccinated group was observed at 12 months from the first vaccination (p= 0.099). More patients from the control group compared to vaccinated patients required active anticancer therapy [4/11 (36%) vs. 8/13 (62%)]. Vaccines based on dendritic cells loaded with Id-protein are safe and induce specific immune response in multiple myeloma patients. Our results suggest that the vaccination could stabilize the disease in approximately two-thirds of patients.<br />Keywords: dendritic cells, immunotherapy, anticancer vaccines, Id-protein, multiple myeloma.
- Subjects :
- Adjuvants, Immunologic
Aged
Case-Control Studies
Dendritic Cells transplantation
Enzyme-Linked Immunosorbent Assay
Female
Hemocyanins immunology
Humans
Hypersensitivity, Delayed
Male
Middle Aged
Multiple Myeloma immunology
Neoplasm Staging
Prognosis
Survival Rate
Vaccination
Cancer Vaccines therapeutic use
Dendritic Cells immunology
Immunotherapy
Inhibitor of Differentiation Proteins immunology
Inhibitor of Differentiation Proteins metabolism
Multiple Myeloma therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0028-2685
- Volume :
- 59
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Neoplasma
- Publication Type :
- Academic Journal
- Accession number :
- 22489700
- Full Text :
- https://doi.org/10.4149/neo_2012_057